神经退行性疾病中的蛋白质聚合
Jiannan Wang1, Lijun Dai2, Zhentao Zhang1
1Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
Chinese medical journal
|September 17, 2025
概括
神经退行性疾病涉及由于粉样蛋白-β和等病态蛋白质聚合物的进展性神经元损失. 了解它们的聚合和传播是开发阿尔茨海默病和帕金森病等疾病的诊断和治疗的关键.
科学领域:
- 神经学 神经学
- 分子生物学分子生物学
- 生物化学 生化学
背景情况:
- 神经退行性疾病是慢性疾病,由渐进的神经元损失定义.
- 关键的疾病包括阿尔茨海默病,帕金森病,亨廷顿病,前叶退化和肌缩性侧面硬化.
- 病理特征包括蛋白质聚合物的积累,如粉样蛋白-β,,α-synuclein和TAR DNA结合蛋白43.
研究的目的:
- 阐明病态蛋白质聚合和传播的分子机制.
- 了解这些聚合物如何触发神经退行.
- 审查目前针对这些蛋白质聚合物的诊断和治疗策略.
主要方法:
- 文献综述总结了关于神经退行性疾病中蛋白质聚合的当前研究.
- 分析涉及蛋白质错折,聚合和传播的分子通路.
- 诊断工具和治疗干预措施的概述.
主要成果:
- 病理性蛋白质形成粉样纤维,以类似子的方式传播,导致神经退行.
- 不同的病理蛋白之间的相互作用可以影响疾病的进展.
- 目前的研究重点是了解治疗开发的这些机制.
结论:
- 了解蛋白质聚合物生物学是神经退行性疾病研究的基础.
- 针对病态蛋白质聚合提供了潜在的治疗途径.
- 需要进一步的研究来完善诊断和治疗策略.
相关概念视频
Amyloid Fibrils
11.7K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.7K
Amyloid Fibrils
6.3K
6.3K
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
The Proteasome
1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K


